UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

June 29, 2023

Date of Report (Date of earliest event reported)

PETVIVO HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Nevada

001-40715

99-0363559

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

5251 Edina Industrial Blvd.

Edina, Minnesota

55439

(Address of principal executive offices)

(Zip Code)

(952) 405-6216

Registrant’s telephone number, including area code

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	PETV	The Nasdaq Stock Market LLC
Warrants to purchase Common Stock	PETVW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

EXPLANATORY NOTE

This Amendment No. 1 to the Current Report on Form 8-K filed by PetVivo Holdings, Inc. (the “Company”) on June 29, 2023 (the “Original Form 8-K”) amends the Original Form 8-K to provide information relative to the rescheduled conference call for Petto discuss the Company’s fiscal year end results.

Item 7.01 Regulation FD Disclosure.

Due to technical difficulties experienced by the teleconference vendor hosting the call, the conference call has been rescheduled for Friday, June 30, 2023 at 10:00 a.m. Eastern Time. No other changes have been made to the Original Form 8-K. This Amendment No. 1 should be read in conjunction with the Original Form 8-K. A copy of the press release providing information relative to the rescheduled conference call is furnished as Exhibit 99.1 to this current report on Form 8-K/A.

The information contained under this Item 2.02 in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. Furthermore, the information contained under this Item 2.02 in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)	Exhibits.

99.1	Press Release of PetVivo Holdings, Inc. dated June 29, 2023
104	Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PETVIVO HOLDINGS, INC.

Date: June 29, 2023	By:	/s/ John Lai
	Name:	John Lai
	Title:	Chief Executive Officer

Exhibit 99.1

PETVIVO HOLDINGS, INC. ANNOUNCES RESCHEDULED EARNINGS CALL FOR THE YEAR ENDED MARCH 31, 2023

MINNEAPOLIS, MN, US, June 29, 2023, PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for companion animals, announced it has rescheduled its earnings conference call for the year ending March 31, 2023. The call will now be held on Friday, June 30, 2023 at 10:00 AM ET (9:00 AM CT).

“Due to a technical glitch by our conferencing services provider, the connection to our scheduled earnings call was compromised,” said John Lai, Chief Executive Officer. “We apologize for the inconvenience and look forward to talking to you at that time.”

Attendees of the live webcast of the conference call and related earnings release materials can register and access the webcast on PetVivo’s Investor Relations website at:

https://audience.mysequire.com/webinar-view?webinar_id=19521825-9284-4391-bfe3-8ed5b4ec0774

A replay of the webcast will be available through the same link following the conference call. Participants can also access the call using the dial-in details below.

Date: Friday, June 30, 2023

Time: 10:00 AM ET (9:00 AM CT)

Dial-in: +1 346 248 7799

Meeting ID: 92979093556

Passcode: 980888

If Attendees cannot connect to the live webcast link identified above within five minutes of the start time, please access the live webcast at the following website:

https://meet.google.com/qon-zwnc-rvb

Dial-in: ‪(US) +1 262-456-3783

PIN: ‪948 813 643#

For more dial-in phone numbers: https://tel.meet/qon-zwnc-rvb?pin=2043377967244

Disclosure Information

PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company’s Investor Relations website, in addition to following the company’s press releases, SEC filings, public conference calls, presentations and webcasts.

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of nineteen patents protects the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG, a veterinarian-administered, intraarticular injection for the treatment of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale to veterinarians.

CONTACT:

John Lai, CEO

PetVivo Holdings, Inc.

Email: [email protected]

(952) 405-6216